<DOC>
	<DOCNO>NCT01500707</DOCNO>
	<brief_summary>This study do ass pharmacokinetics SCH 900800 participant moderate severe Parkinson 's Disease ( PD ) treat L-DOPA .</brief_summary>
	<brief_title>Single Dose Study Assess Pharmacokinetics SCH 900800 Subjects With Parkinson 's Disease Being Treated With Levodopa ( L-DOPA ) ( P08235 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 35 Diagnosis idiopathic Parkinson 's disease ( PD ) characterize least two follow : rest tremor , bradykinesia , rigidity ( must either rest tremor bradykinesia ) ; participant must either moderate severity PD moderate severe PD motor fluctuation For participant moderate PD , Hoehn Yahr stage must ≥1.5 ≤4 `` '' state Screening ; participant moderate severe PD motor fluctuation , Hoehn Yahr stage must ≥2 ≤4 `` '' state Screening On stable antiparkinson treatment regimen include LDOPA/carbidopa least 3 week prior screen clinically stable time randomization ( predose ) , first morning dose LDOPA must 100 mg great LDOPA therapy ≥ 6 month prior screen If take adjunct PD medication ( amantadine , anticholinergic , DOPA decarboxylase inhibitor , dopamine agonist , entacapone , rasagiline selegiline ) must stable dose least 4 week prior randomization study Females , fertile , willing use medically acceptable method contraception 3 month prior screen 2 month stop study drug Nonvasectomized male must agree use condom spermicide ( marketed country ) abstain sexual intercourse trial 3 month stop study drug Pregnant intending become pregnant within 3 month end study therapy Breastfeeding Systolic blood pressure ( BP ) ≥150 mm Hg diastolic BP ≥90 mm Hg Screening BP recheck prior randomization . If antihypertensive medication use control BP , dose antihypertensive medication must stable least 2 week prior randomization History clinically significant cardiovascular disease procedure prior randomization , include , limited , myocardial infarction , prolong QT interval correct heart rate , clinically important ECG abnormality , angioplasty , stable unstable angina , heart failure History clinically significant uncontrolled neurologic ( Parkinson 's disease ) endocrine , gastrointestinal , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug include history presence inflammatory bowel disease , ulcer , gastrointestinal rectal bleeding ; history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; history pancreatic injury pancreatitis ; history presence liver disease liver injury ; history presence impair renal function indicate clinically significant elevation creatinine , blood urea nitrogen ( BUN ) /urea , urinary albumin , clinically significant urinary cellular constituent ; history urinary obstruction difficulty void Infectious disease within 4 week prior drug administration Positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Clinically significant complication Parkinson 's disease Parkinson 's disease treatment , include severe , disable motor fluctuation allow subject maintain stable LDOPA/carbidopa dose ; disable dyskinesia ; hallucination ; dementia History alcohol drug abuse past 2 year Donation blood past 60 day Previously receive SCH 900800 Currently participate another clinical study participate clinical study investigational drug surgical procedure administer , within 30 day baseline Study staff personnel family member study staff personnel Use 10 cigarette equivalent tobacco use per day History malignancy A form parkinsonism idiopathic Parkinson 's disease ( e.g. , multiple system atrophy progressive supranuclear palsy ) Imminent risk selfharm harm others , base clinical interview response Columbia Suicidality Severity Rating Scale . Exclude participant reporting suicidal ideation intent , without plan past 2 month suicidal behavior past 6 month Use strong moderate inhibitor inducer cytochrome P ( CYP ) 3A4 isoenzyme ( e.g . St John 's Wort , ketoconazole , ritonavir , rifampin , macrolide antibiotic , calcium channel blocker include diltiazem , verapamil , etc . ) within 30 day ; inhibitor enzyme CY2D6 within 14 day ; Proton Pump Inhibitors histamine ( H2 ) Receptor Blockers within 14 day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>